MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
More news: Health / Surgery
Written by / Agency / Source: NEC Corporation
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

University of the Ryukyus and NEC Discover a Novel Diagnostic Biomarker for Acute Adult T-cell Leukemia/lymphoma - Discovery of elevated levels of soluble tumor necrosis factor receptor 2 - U-Ryukyu.ac.jp / NEC.com
University of the Ryukyus and NEC Discover a Novel Diagnostic Biomarker for Acute Adult T-cell Leukemia/lymphoma

 

NewswireToday - /newswire/ - Okinawa, Japan, 2020/03/23 - Discovery of elevated levels of soluble tumor necrosis factor receptor 2 - U-Ryukyu.ac.jp / NEC.com. NEC; TSE: 6701

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health / Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

A study jointly conducted by Dean and Professor Takuya Fukushima, M.D., Ph.D., Graduate School of Health Sciences, University of the Ryukyus (u-ryukyu.ac.jp), and NEC Corporation has discovered a novel diagnostic biomarker for acute adult T-cell leukemia/lymphoma and been published in Blood Advances, a medical journal from the American Society of Hematology.

Key points of the announcement:

• A comprehensive proteomic analysis of samples from the Okinawa HTLV-1/ATL Biobank revealed that the expression level of soluble tumor necrosis factor receptor 2 (sTNFR2) was elevated in ATL patients compared to asymptomatic HTLV-1 carriers;
• As a biomarker, sTNFR2 in the blood plasma of ATL patients is expected to be more sensitive and more specific than other biomarkers previously reported. Although it is known that several proteins are found at higher levels in ATL patients, this study has discovered a proteomic biomarker with enhanced sensitivity and specificity;
• Observation of sTNFR2 expression levels may help in the early diagnosis of ATL onset in HTLV-1 carriers. This may also help ATL patients through improvement of therapeutic outcomes, evaluation of treatment response, and prediction of prognosis.

Adult T-cell leukemia/lymphoma (ATL) is a mature T-cell neoplasm associated with human T-cell leukemia virus type-1 (HTLV-1). Studies have shown that Japan has the largest population of HTLV-1 carriers, especially the Okinawa and Kyushu regions, and correspondingly a high incidence of ATL (reference 1, 2). The main routes of transmission of HTLV-1 are vertical transmission from an infected mother to child through breastfeeding, and horizontal (sexual) transmission.

A 2008 to 2010 nationwide survey conducted by the scientific research arm of Japan's Ministry of Health, Labor and Welfare estimated that there is a total of 1,080, 000 carriers in Japan, and that the proportion of carriers in the metropolitan Kanto and Kinki regions has been on the rise (reference 3). The majority of HTLV-1 carriers remain asymptomatic throughout their lives, with only 5% exhibiting clinical features of ATL.

Nevertheless, treatment of ATL remains exceptionally challenging, and the acute and lymphoma subtypes are known to be aggressive. Aggressive ATL patients typically have a poor prognosis, with a median survival time of 8 to 10 months. To diagnose early ATL onset and improve the treatment of ATL, research is being conducted to identify ATL risk factors among HTLV-1 carriers, and although a high proviral load is known to be a risk factor for ATL progression, a definitive factor that can be used to predict the onset of ATL has yet to be identified. Moreover, ATL is known to increase the levels of plasma proteins such as lactase dehydrogenase and soluble interleukin-2 receptor, but this increase is not specific to ATL and is not as useful as a predictor of ATL onset.

According to the Okinawa HTLV-1/ATL Research Network, a research group which is connected to various hospitals in Okinawa, there are approximately 70 aggressive ATL cases annually in Okinawa. Professor Takuya Fukushima and his colleagues partnered with NEC Corporation to form a joint research team with the objective of discovering a new biomarker that will enable the early detection of ATL. This was achieved by performing a comprehensive blood-based proteomic analysis of blood plasma specimens from the Okinawa HTLV-1/ATL biobank to compare asymptomatic HTLV-1 carriers (AC) and ATL patients.

Through SOMAscan, a proteomic analysis platform provided by US-based SomaLogic Inc., expression levels of 1,305 plasma proteins were analyzed in 40 AC and 40 ATL patients. From this study, 333 types of proteins were found to have significantly different levels in the two study groups. Subsequently, those proteins with especially large differences were further analyzed using ELISA. Results showed that soluble tumor necrosis factor receptor 2 (sTNFR2) was found in remarkably elevated levels in ATL patients, especially acute ATL, compared to AC subjects.

Tumor necrosis factor (TNF) is a cytokine, and the subtype, TNF-α, induces apoptosis of solid tumor cells. TNF-α is also known to be involved in the induction of inflammation and apoptosis, and the inhibition of tumorigenesis. TNFR2 is one of the receptors of TNF-α, and is involved in the proliferation of tumors. sTNFR2 refers to TNFR2 that have shed from the surface of cells and are freely floating in the blood. This study has also revealed that TNFR2 are highly expressed on acute ATL cell surfaces. To date, there have been no research findings indicating elevated TNFR2 levels in ATL patients, and the results of this study represent the potential clinical utility of sTNFR2 as a biomarker to diagnose acute ATL.

Looking ahead, the clinical significance of elevated sTNFR2 levels in onset prediction, early diagnosis, and prognosis prediction should be examined. Moreover, analyzing the mechanism by which TNFR2 is released from the surface of cells may prove to be important in paving the way for new treatment options.

References

1. Gessain A, Cassar O (2012) Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol 3: 388.
2. Nosaka K, Iwanaga M, Imaizumi Y, Ishitsuka K, Ishizawa K, Ishida Y, Amano M, Ishida T, Uike N, Utsunomiya A, Ohshima K, Kawai K, Tanaka J, Tokura Y, Tobinai K, Watanabe T, Uchimaru K, Tsukasaki K (2017) Epidemiology and clinical features of adult T-cell leukemia-lymphoma in Japan, 2010-2011: A nationwide survey. Cancer Sci 108(12): 2478-2486
3. Satake M, Yamaguchi K, Tadokoro K (2012) Current prevalence of HTLV-1 in Japan as determined by screening of blood donors. J Med Virol 84: 327-335.

About NEC Corporation

NEC Corporation (nec.com) is a leader in the integration of IT and network technologies that benefit businesses and people around the world. The NEC Group globally provides "Solutions for Society" that promote the safety, security, efficiency and equality of society. Under the company's corporate message of "Orchestrating a brighter world," NEC aims to help solve a wide range of challenging issues and to create new social value for the changing world of tomorrow.

NEC is a registered trademark of NEC Corporation. All Rights Reserved. Other product or service marks mentioned herein are the trademarks of their respective owners. ©2020 NEC Corporation.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health / Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: NEC Corporation

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health / Surgery articles,
CATCH Visitors via Your Competitors Announcements!


University of the Ryukyus and NEC Discover a Novel Diagnostic Biomarker for Acute Adult T-cell Leukemia/lymphoma

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any NEC Corporation securities in any jurisdiction including any other companies listed or named in this release.

Health / Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From NEC Corporation / Company Profile


Read Health / Surgery Most Recent Related Newswires:

The American Psychiatric Association Selects Wiley to Publish its Open Access Journal Psychiatric Research and Clinical Practice
South Carolina Launches Emergency Supply Portal to Connect Providers with Organizations in Need
EHR Investments Increase as Governments and Healthcare Authorities Focus on Interoperability Finds Frost & Sullivan
South Carolina’s Humimic Medical Arming Healthcare Workers for the COVID-19 War
SCBIO Executive Erin Ford Appointed to South Carolina District Export Council for 2020-2021
Change Healthcare Recognized by Frost & Sullivan for Accelerating Claims Processing with its Intelligent Healthcare Network™ Blockchain Technology
SCBIO CEO Sam Konduros Named to South Carolina Chamber Executive Committee
Frost & Sullivan Defines Top Femtech Global Opportunities by 2024
Frost & Sullivan Highlights on Impact of the Coronavirus on Business
Global Healthcare to Soar Above Trillion in 2020 with Consumerism and Outcome-based Care Models Finds Frost & Sullivan
Demand for CROs Rises to Strike Evolving Clinical Trial Models for Target Therapies Reports Frost & Sullivan
PointClickCare Integrated Care Coordination Platform Applauded by Frost & Sullivan
Inkwood Research Publishes Global Genetic Testing Market Forecast 2019-2027
NEC and VAXIMM Announce Collaboration to Advance Personalized Neoantigen Cancer Vaccines
Alopecia Hair Loss Treatment Market is Advancing At A CAGR of 5.51% by 2027 According to Inkwood Research

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  BizJobs.com





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)